UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners

UCSF Life Sciences Building will bring research, innovation, specialty care clinics, and world-class cancer therapy to San Francisco’s central waterfront.

Here is your snapshot of all therapeutic options that the FDA approved in October 2024 spanning tumor types.

Hope Rugo, MD, FASCO, discusses the FDA approval of inavolisib, how it will be incorporated into care, and the patient population evaluated in INAVO120.

Terence W. Friedlander, MD, discusses the design and methodology of the Duravelo-2 study of zelenectide pevedotin in advanced/metastatic urothelial cancer.

Terence W. Friedlander, MD, discusses emerging agents of interest in urothelial carcinoma.

Dr Taylor discusses the significance of the FDA approval of vorasidenib for patients with IDH-positive grade 2 astrocytoma or oligodendroglioma.

Panelists discuss how addressing unmet needs in patient selection, resistance mechanisms, and long-term outcomes can enhance the efficacy of antibody-drug conjugates in breast cancer treatment.

Panelists discuss how, despite the investigational status of agents like patritumab deruxtecan (HER3-DXd) and datopotamab deruxtecan (Dato-DXd), it’s crucial for community oncologists to be aware of the treatment-related adverse effects (TRAEs) associated with these therapies and to consider effective management strategies as reported in clinical trials.

Panelists discuss how ongoing clinical trials of investigational antibody-drug conjugates (ADCs) are advancing treatment options for breast cancer, particularly in patients with active brain metastases and advanced disease.

Panelists discuss how the multidisciplinary team plays a crucial role in managing treatment-resistant adverse effects for patients receiving antibody-drug conjugates, emphasizing collaboration among oncologists, pharmacists, nurses, and specialists to optimize patient care and ensure comprehensive support.

Panelists discuss how management and monitoring for pneumonitis and cardiotoxicity in trastuzumab deruxtecan (T-DXd) is similar to trastuzumab emtansine (T-DM1), while also emphasizing the need for awareness of adverse effects such as peripheral neuropathy, thrombocytopenia, and hepatotoxicity, along with strategies for their management and when to consider therapy modifications.

Terence W. Friedlander, MD, discusses adverse effects that are associated with standard enfortumab vedotin in bladder cancer.

Researchers will investigate aggressive prostate cancer from a mechanistic, biomarker and therapeutic perspective.

Experts on breast cancer provide clinical insights on the management of pneumonitis associated with trastuzumab deruxtecan.

Experts on breast cancer discuss the potential adverse events related to trastuzumab deruxtecan (T-DXd).

Terence W. Friedlander, MD, discusses updates in the frontline management of bladder cancer.

A UCSF-led study alerts transwomen and physicians to interpret standard screening guidelines with caution.

A 100-mg dose of tarlatamab was safe and showed particularly robust activity in patients with DLL3-positive neuroendocrine prostate cancer.

The milestone robotic procedure is a complex gastrointestinal surgery.

Treatment with nivolumab plus cabozantinib yielded responses in patients with non-clear cell renal cell carcinoma.

Eating more fruits, nuts and vegetables each day – along with fewer animal products – is associated with a nearly 50% reduction in the risk of prostate cancer progression.

Medical professionals discuss the recently published real-world evidence presented at the American Thyroid Association 2023 Conference.

Hyunseok Kang, MD, discusses the importance of balancing toxicities and other factors when initiating first-line treatments for patients with refractory differentiated thyroid cancer (DTC), while emphasizing the need to set clear goals and communicate potential adverse reactions before allowing patients to make informed decisions.

Targeted therapy, genomics, and treatment disparities were among the topics that were presented by researchers from UCSF at the 2024 AACR conference.

Drs Graff, Mahtani, McCann, and Rugo share moments that sparked their interest in oncology and setbacks they overcame when building their careers.

UCSF researcher to lead multicenter precision medicine trial for juvenile myelomonocytic leukemia.

Hope S. Rugo, MD, draws on her own journey as a woman in oncology to provide insights on navigating career transitions and building support networks.

Hope Rugo, MD, discusses the evolution of antibody-drug conjugates in hormone receptor–positive, HER2-positive, and HER2-low breast cancer.

Laura A. Huppert, MD, discusses data informing the sequence of immunotherapy and chemotherapy regimens in early-stage triple-negative breast cancer.

Hope S. Rugo, MD, FASCO, shares progress made with ADCs and the interest in moving these agents up in the HR-positive/HER2-negative breast cancer paradigm.